249 related articles for article (PubMed ID: 25351958)
1. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
Ozanne J; Prescott AR; Clark K
Biochem J; 2015 Jan; 465(2):271-9. PubMed ID: 25351958
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule screening identifies inhibition of salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells.
Sundberg TB; Choi HG; Song JH; Russell CN; Hussain MM; Graham DB; Khor B; Gagnon J; O'Connell DJ; Narayan K; Dančík V; Perez JR; Reinecker HC; Gray NS; Schreiber SL; Xavier RJ; Shamji AF
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12468-73. PubMed ID: 25114223
[TBL] [Abstract][Full Text] [Related]
3. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages.
Clark K; MacKenzie KF; Petkevicius K; Kristariyanto Y; Zhang J; Choi HG; Peggie M; Plater L; Pedrioli PG; McIver E; Gray NS; Arthur JS; Cohen P
Proc Natl Acad Sci U S A; 2012 Oct; 109(42):16986-91. PubMed ID: 23033494
[TBL] [Abstract][Full Text] [Related]
5. Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.
Tarpley M; Abdissa TT; Johnson GL; Scott JE
Anticancer Res; 2014 Apr; 34(4):1629-35. PubMed ID: 24692691
[TBL] [Abstract][Full Text] [Related]
6. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
7. Bosutinib Attenuates Inflammation via Inhibiting Salt-Inducible Kinases in Experimental Model of Intracerebral Hemorrhage on Mice.
Ma L; Manaenko A; Ou YB; Shao AW; Yang SX; Zhang JH
Stroke; 2017 Nov; 48(11):3108-3116. PubMed ID: 29018127
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages.
Darling NJ; Toth R; Arthur JS; Clark K
Biochem J; 2017 Feb; 474(4):521-537. PubMed ID: 27920213
[TBL] [Abstract][Full Text] [Related]
9. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Levinson NM; Boxer SG
PLoS One; 2012; 7(4):e29828. PubMed ID: 22493660
[TBL] [Abstract][Full Text] [Related]
10. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
11. SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype.
Lombardi MS; Gilliéron C; Dietrich D; Gabay C
J Leukoc Biol; 2016 May; 99(5):711-21. PubMed ID: 26590148
[TBL] [Abstract][Full Text] [Related]
12. A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines.
Vojvodic M; Hansford LM; Morozova O; Blakely KM; Taylor P; Fathers KE; Moffat J; Marra M; Smith KM; Moran MF; Kaplan DR
Curr Drug Discov Technol; 2013 Dec; 10(4):283-304. PubMed ID: 23701117
[TBL] [Abstract][Full Text] [Related]
13. Neuroimmunological communication via CGRP promotes the development of a regulatory phenotype in TLR4-stimulated macrophages.
Baliu-Piqué M; Jusek G; Holzmann B
Eur J Immunol; 2014 Dec; 44(12):3708-16. PubMed ID: 25316186
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib.
Alkebsi L; Wang X; Ohkawara H; Fukatsu M; Mori H; Ikezoe T
Int J Hematol; 2021 Mar; 113(3):441-455. PubMed ID: 33392972
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Wermuth PJ; Jimenez SA
PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo.
Fraser CK; Lousberg EL; Kumar R; Hughes TP; Diener KR; Hayball JD
Exp Hematol; 2009 Dec; 37(12):1435-44. PubMed ID: 19786067
[TBL] [Abstract][Full Text] [Related]
17. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
18. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Thienelt CD; Green K; Bowles DW
Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer's disease models.
Lonskaya I; Hebron ML; Selby ST; Turner RS; Moussa CE
Neuroscience; 2015 Sep; 304():316-27. PubMed ID: 26235435
[TBL] [Abstract][Full Text] [Related]
20. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
Isfort S; Crysandt M; Gezer D; Koschmieder S; Brümmendorf TH; Wolf D
Recent Results Cancer Res; 2018; 212():87-108. PubMed ID: 30069626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
